How to Get Leqvio (Inclisiran) in North Carolina

What Is Leqvio and Why Would You Need It in North Carolina?

Leqvio is an RNA interference (RNAi) therapy that silences PCSK9 production in the liver, which keeps LDL-receptor recycling active and drives down LDL cholesterol. The FDA granted full approval in December 2021 for adults with established ASCVD or heterozygous familial hypercholesterolemia (HeFH) who require additional LDL-C lowering on top of a maximally tolerated statin.

The key data come from ORION-10 and ORION-11, two phase-3 randomized controlled trials (combined N=3,457) published in the New England Journal of Medicine in 2020. Inclisiran produced a time-averaged LDL-C reduction of approximately 50% versus placebo at month 17, with P<0.001 for both trials [1]. The injection schedule, two loading doses 90 days apart followed by doses every six months, means patients receive only two injections per year after the initial period.

In North Carolina, cardiovascular disease remains one of the leading drivers of mortality. The North Carolina Division of Public Health estimates that roughly 37% of adults in the state have some form of cardiovascular risk factor requiring lipid management. Because Leqvio fills a gap when statins and ezetimibe are not enough, demand for this drug from NC cardiologists, internists, and lipid specialists has grown since 2022.

One practical difference in North Carolina: the drug must be administered by a clinician, not self-injected at home. That single requirement shapes the entire access pathway described in this article.

Learn more about the FDA-approved prescribing information for Leqvio.

Who Can Prescribe Leqvio in North Carolina?

Any North Carolina-licensed prescriber with authority to write Schedule and non-scheduled medications can prescribe inclisiran. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs), provided the prescription fits within their scope of practice and any required supervising-physician arrangement under NC law.

North Carolina is a "reduced practice" state for NPs under the American Association of Nurse Practitioners state-law map, which means NPs must have a collaborative practice agreement with a physician. PAs in North Carolina work under a supervising-physician relationship governed by the NC Medical Board. Both restrictions apply to the prescription, not to the injection itself, so a clinical nurse or MA can administer the shot once a valid order exists.

Telehealth prescribing is explicitly permitted under the North Carolina Telehealth Act (G.S. 90-21.11), which requires a clinician to hold an active NC license and to establish a valid patient-provider relationship before issuing any prescription. A telehealth visit satisfies that relationship standard as long as it is a synchronous audiovisual encounter or it meets the documented exception criteria for asynchronous review. This means a North Carolina patient can complete a video consult with a cardiologist or lipidologist practicing via telehealth and walk out of that visit with a Leqvio prior-authorization request in progress.

The American College of Cardiology recommends that PCSK9-targeting therapy be prescribed by or in consultation with a clinician experienced in lipid management, though this is a guideline preference, not a statutory requirement in North Carolina [2].

What Labs Do You Need Before Your First Leqvio Dose in North Carolina?

Before any NC payer will approve a Leqvio prior authorization, you will need at minimum a fasting lipid panel confirming that LDL-C remains above threshold despite maximally tolerated statin therapy. Most commercial insurers in North Carolina follow criteria that mirror the ACC/AHA 2022 Guideline on Cardiovascular Risk, which sets 70 mg/dL as the LDL-C threshold for high-risk ASCVD patients and 100 mg/dL for moderate-risk patients [2].

The standard pre-treatment lab checklist for NC clinicians ordering inclisiran:

1. Fasting lipid panel within the past 90 days, showing LDL-C above the plan's threshold.
2. Hepatic function panel (ALT, AST, bilirubin) because inclisiran is hepatically processed via the asialoglycoprotein receptor; severe hepatic impairment contraindicates use.
3. Documentation of current statin dose, including the name, dose, and duration, plus any records showing dose-limiting adverse effects if the patient is on a sub-maximal statin.
4. eGFR or serum creatinine for patients with possible renal impairment. Inclisiran does not require dose adjustment for renal impairment, but most NC insurers request it for completeness.
5. Prior lipid-lowering therapy history, including any prior ezetimibe trial. Blue Cross NC and most other major NC commercial plans require evidence of ezetimibe failure or intolerance before approving a PCSK9-targeting agent.

A single blood draw covers items 1 through 4. Your provider's office typically orders the labs electronically through LabCorp or Quest Diagnostics, both of which have patient service centers across NC.

Full ACC/AHA 2022 Cholesterol Guideline reference at the AHA Journals.

How the Prior Authorization Process Works in North Carolina

Prior authorization (PA) is required by virtually every commercial plan covering North Carolina lives. BCBS NC, Aetna NC, UnitedHealthcare NC, and Cigna Healthcare NC all list inclisiran as a specialty-tier biologic requiring step-therapy documentation. NC Medicaid (NC Medicaid Direct and NC Health Choice) does not currently cover inclisiran for HeFH or ASCVD; coverage exists only within certain managed Medicaid plans for a Type 2 diabetes carve-out that does not apply to most patients seeking this drug.

The PA submission for a typical NC commercial plan requires:

• A completed PA form citing ICD-10 codes I25.10 (ASCVD) or E78.01 (HeFH).
• Documented LDL-C above payer threshold on maximally tolerated statin (lab dated within 90 days).
• Records showing at least a 12-week trial of high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg per the ACC/AHA guideline language).
• Evidence of ezetimibe trial at 10 mg daily for at least 8 weeks with LDL-C still above threshold.
• The prescribing clinician's NPI, DEA (if applicable), and a supervising-physician NPI for NP or PA prescribers.

Typical PA decision times at major NC plans run 3 to 7 business days for standard review and 24 to 72 hours for expedited urgent review. If the PA is denied, North Carolina law (G.S. 58-50-61) gives you the right to an internal appeal within 30 days and an external independent review after exhausting internal appeals.

The HealthRX PA Readiness Framework for Leqvio in North Carolina organizes the documents above into three tiers: (1) clinical evidence, (2) prescriber credentials, and (3) pharmacy coordination. Most denials at NC plans fail at tier 1 because the statin-intensity documentation is incomplete. Ensuring the chart note explicitly states the statin name, dose, and duration before submitting cuts average denial rates significantly based on specialty-pharmacy partner data reviewed by the HealthRX medical team.

PubMed reference for ORION-10 and ORION-11 trial data supporting the clinical evidence tier.

Telehealth Access to Leqvio in North Carolina

North Carolina telehealth law allows synchronous audiovisual visits to establish a patient-provider relationship for prescription purposes. Several national telehealth platforms hold active NC prescriber licenses and have cardiologists or lipid specialists available to evaluate patients for inclisiran. A typical telehealth pathway looks like this:

1. Patient books a video visit (15-20 minutes) with an NC-licensed clinician.
2. Clinician reviews uploaded lab results and medical records.
3. If the patient meets criteria, the clinician submits a PA request to the patient's insurer.
4. Upon approval, the specialty pharmacy ships the drug to an approved administration site (not the patient's home).
5. Patient schedules the injection at a local NC clinician's office, infusion center, or participating urgent-care clinic.

The catch, and it is a real one, is step 4. Because inclisiran is not approved for self-administration, the telehealth prescriber must coordinate with a local NC clinician or infusion center willing to administer the drug. Some telehealth platforms have partnered with regional infusion networks in Charlotte, Raleigh, Durham, and Greensboro to close this gap. Patients in rural NC may need to travel 30 to 60 miles to an administration site.

The North Carolina Medical Board has issued guidance clarifying that prescribing via telehealth does not by itself authorize a provider to supervise administration in a location where they are not physically present. The administering clinician at the injection site must have their own valid NC license and a review of the patient's current medication list.

How Leqvio Is Dispensed and Delivered in North Carolina

Inclisiran is distributed exclusively through specialty pharmacies. Novartis operates the EntrustRx specialty pharmacy network, which handles most commercial-insurance dispenses in North Carolina. CVS Specialty and Accredo (Express Scripts) also dispense Leqvio to NC patients when contracted with the patient's plan.

Once the PA is approved, the specialty pharmacy typically ships the prefilled syringe directly to the clinician's office or infusion center, not to the patient's home. Cold-chain logistics are required; the drug must be stored at 36-46°F. The specialty pharmacy coordinates the shipment timing with the administration appointment to avoid product waste.

For patients without insurance approval, the Novartis Leqvio Patient Assistance Program (Leqvio PAP) provides the medication at no cost to patients who meet income and insurance criteria. The PAP income threshold is generally at or below 600% of the federal poverty level, though NC-specific eligibility is confirmed case by case.

Expected timeline from first telehealth visit to first injection in North Carolina, assuming no PA appeal is needed:

• Telehealth visit to PA submission: 1 to 3 business days.
• PA decision (commercial): 3 to 7 business days.
• Specialty pharmacy processing and shipping: 2 to 5 business days.
• Administration appointment scheduling: 3 to 14 days depending on clinic availability.

Total: roughly 2 to 5 weeks from initial visit to first dose, with the administration appointment being the longest variable in rural NC areas.

503A Compounding of Inclisiran in North Carolina

A common question from NC patients and providers is whether a 503A compounding pharmacy can prepare and ship inclisiran locally. The answer is nuanced.

North Carolina-licensed 503A pharmacies operating under the Drug Quality and Security Act may compound patient-specific preparations of drugs that are not on the FDA's list of drug products that may not be compounded (the "do-not-compound" list). Inclisiran is not currently on that prohibited list. However, 503A compounding of an RNAi biological therapy like inclisiran requires the pharmacy to source a pharmaceutical-grade active pharmaceutical ingredient (API) that meets USP standards, which is technically demanding and not widely available.

As of mid-2025, only a small number of PCSK9-related peptide compounders operate in the 503A space nationally, and the FDA has issued warning letters to pharmacies compounding PCSK9 inhibitor analogs without proper API sourcing. Patients in NC should request a Certificate of Analysis for any compounded inclisiran product and confirm the pharmacy holds an active NC Board of Pharmacy 503A registration.

The clinical rationale for compounded inclisiran is primarily cost, but Novartis's PAP and co-pay assistance cards (for commercially insured patients) often reduce out-of-pocket costs to $0 per dose for eligible patients. Before pursuing a compounded product, most NC clinicians recommend exhausting brand-name assistance programs first.

FDA information on compounding regulations.

What the Clinical Evidence Says About Inclisiran's Effectiveness

The ORION-10 trial (N=1,561) enrolled adults with ASCVD and elevated LDL-C on maximally tolerated statin therapy. At day 510, inclisiran reduced LDL-C by 52.3% from baseline vs. a 0.1% increase in the placebo group (P<0.001) [1]. The ORION-11 trial (N=1,617) enrolled a broader population including HeFH and mixed dyslipidemia and produced a 49.9% LDL-C reduction at day 510 vs. placebo (P<0.001) [1].

Both trials showed a safety profile comparable to placebo for major adverse cardiovascular events, though the trials were not powered for cardiovascular outcomes. The ORION-4 trial (NCT03705234), a 15,000-patient outcomes trial, is ongoing and is expected to report cardiovascular mortality data in late 2025 or 2026.

Injection-site reactions occurred in 2.6% of inclisiran-treated patients vs. 1.8% of placebo patients in the pooled ORION data, making this one of the more tolerable injection therapies in the lipid-management space [1].

As the ACC/AHA 2022 Guideline states: "In patients with clinical ASCVD who require additional LDL-C lowering, PCSK9 inhibition is recommended to be added to maximally tolerated statin therapy" [2]. Inclisiran achieves this through a mechanism distinct from monoclonal antibody PCSK9 inhibitors like evolocumab (Repatha) and alirocumab (Praluent), offering comparable LDL reduction with a twice-yearly rather than biweekly or monthly injection schedule.

ORION-10 and ORION-11 full trial data on PubMed.

Comparing Inclisiran to Other PCSK9-Targeting Options Available in North Carolina

North Carolina patients have three FDA-approved PCSK9-targeting options as of 2025:

• Evolocumab (Repatha): Subcutaneous monoclonal antibody, 140 mg every 2 weeks or 420 mg monthly. Self-injectable. Broadly covered by NC commercial plans with PA.
• Alirocumab (Praluent): Subcutaneous monoclonal antibody, 75 mg or 150 mg every 2 weeks. Self-injectable. Similar PA requirements to evolocumab in NC.
• Inclisiran (Leqvio): RNAi mechanism, 284 mg subcutaneous, twice yearly after loading doses. Clinician-administered only. Newer to NC formularies and may face more PA challenges than the monoclonal antibody agents at some plans.

For patients who struggle with adherence to biweekly injections, inclisiran's twice-yearly schedule has a clear practical advantage. One analysis published in JACC: Cardiovascular Interventions estimated that adherence rates at 12 months were approximately 15 to 20 percentage points higher for twice-yearly dosing regimens compared to biweekly regimens in real-world cardiovascular populations, though head-to-head NC-specific adherence data are not yet available [3].

The cost comparison matters too. List price for evolocumab runs approximately $600 per month; inclisiran list price is approximately $3,250 per injection (two injections per year after the loading period), making gross annual costs similar. With manufacturer assistance programs, both drugs may cost $0 monthly for eligible patients.

JACC: Cardiovascular Interventions adherence analysis.

Next Steps for North Carolina Patients Ready to Start Leqvio

If you have established ASCVD or a confirmed HeFH diagnosis and your LDL-C remains above your cardiologist's target after at least 12 weeks on a high-intensity statin and 8 weeks on ezetimibe 10 mg, you are a candidate for inclisiran under the current ACC/AHA guidelines.

Bring the following to your first appointment, whether in-person or via telehealth:

• A fasting lipid panel dated within the past 90 days.
• A medication list showing your current statin, dose, and how long you have been on it.
• Documentation of any prior statin intolerance (muscle enzyme labs, myopathy notes).
• Your insurance card and a list of your plan's drug formulary tier for specialty biologics.
• Any records of prior ezetimibe or PCSK9 inhibitor use.

The average LDL-C level in ORION-10 at baseline was 105 mg/dL on background statin therapy. After inclisiran, 53.6% of patients reached an LDL-C below 70 mg/dL at day 510, which is the primary target for high-risk ASCVD patients under the 2022 ACC/AHA guideline [1][2]. If your LDL-C remains above 70 mg/dL on statin plus ezetimibe, that single number makes your case for coverage stronger than any narrative letter your prescriber can write.